The percentages of surgeons who responded that the following tumor-marker and other related information was “almost always” available to inform their decision to perform surgery ranged from 60 to 73 %, depending on the type of information, as follows: HER2 (61 %), ER/PR (60 %), type/grade (70 %), lymph node status (73 %), and tumor size (71 %). The gene discussed is ERBB2; the disease is neoplasm.